Beactica Therapeutics' TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024

Contributed by: PR Newswire

Tags

BEACTICA-THERAPEUTICS

More Like This

Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

PR Newswire associated0

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire associated0

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

Long-term treatment data for lecanemab to be presented at AAIC 2024